Generic Name and Formulations:
Ezetimibe 10mg; tabs.
Merck & Co., Inc.
Indications for ZETIA:
Adjunct to diet, alone or in combination with an HMG-CoA reductase inhibitor (statin), in primary hyperlipidemia (heterozygous familial and non-familial) to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C. Adjunct to diet and in combination with fenofibrate to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in mixed hyperlipidemia. Adjunct to other lipid-lowering treatments, or if these treatments are unavailable, with atorvastatin or simvastatin to reduce elevated total-C and LDL-C in homozygous familial hypercholesterolemia. Adjunct to diet in homozygous familial sitosterolemia to reduce elevated sitosterol and campesterol.
≥10yrs: 10mg once daily. Concomitant bile acid sequestrants: give ezetimibe either ≥2hrs before or ≥4hrs after. Concomitant simvastatin doses >20mg in moderate-to-severe renal impairment: use caution and monitor closely.
<10yrs: not recommended.
The use of ezetimibe with a statin is contraindicated in active liver disease or unexplained persistent elevations in serum transaminases. Statins are contraindicated in pregnancy and nursing.
Moderate to severe hepatic insufficiency: not recommended. If given with a statin: monitor liver function initially and then as recommended for the statin. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant fibrates (except fenofibrate): not recommended. Potentiates cyclosporine. Potentiated by fenofibrate, gemfibrozil, cyclosporine. Monitor warfarin, cyclosporine. Antagonized by cholestyramine.
Cholesterol absorption inhibitor.
Upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, dizziness, headache, fatigue; rare: myopathy/rhabdomyolysis; w. statin: nasopharyngitis, myalgia, back pain, increased serum transaminases.
For more information on statins, see their entries.
Tabs—30, 90, 500, 5000
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Outcomes in SCCHN Improved With Swap of Docetaxel for 5-FU in Palliative Regimen
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|